BioSpace News Archive

Ashvattha Therapeutics today announced that the first patient has been dosed with D-4517.2, a subcutaneously administered anti-angiogenic therapeutic, in a Phase 2 chronic dosing study. The open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet AMD and DME.

BioSig Technologies, Inc. announced that the U.S. Patent and Trademark Office has awarded several new utility patents covering the Company’s PURE EP™ digital signal processing technology.

Eterna Therapeutics Inc. today announced the appointment of James Bristol, Ph.D., to its Board of Directors.

NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?”.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2023 operating and financial results webcast on Wednesday, November 8, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Civica Inc. is proud to announce that pharmaceutical industry leader Bouwien Smits has joined Civica as the new Site Vice President and General Manager of the company’s new sterile injectable manufacturing facility.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.

IO Biotech today announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC) being held in San Diego, California from November 1-5, 2023.

Longboard Pharmaceuticals, Inc. today announced that members of its senior management team will present at three upcoming investor conferences in November.

Atara Biotherapeutics Announces Expanded Global Tab-cel ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results.